Literature DB >> 11854246

Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses.

Marta Feldmesser1, Aron Mednick, Arturo Casadevall.   

Abstract

Cryptococcus neoformans, an encapsulated yeast, is a common cause of life-threatening meningoencephalitis in immunosuppressed patients. We previously observed that administration of a monoclonal antibody (MAb) to the capsular polysaccharide to mice with pulmonary infection prolonged survival and enhanced granulomatous inflammation without reducing lung CFU. To understand the mechanism of MAb action, we studied leukocyte recruitment and cytokine profiles in lungs of A/JCr mice. B lymphocytes were the predominant cell type in lung infiltrates, comprising 15 to 30% of the leukocytes. Despite alterations in histological appearance, fluorescence-activated cell sorter analysis revealed no significant difference in total numbers of lung leukocytes in MAb-treated mice and controls. Differences in the immune response to C. neoformans between MAb-treated mice and controls included (i) an increase in the percentage of granulocytes among lung leukocytes on day 14, (ii) higher macrophage surface expression of CD86 on day 28, (iii) larger amounts of IL-10 in lung homogenates at day 7, (iv) a trend toward smaller amounts of gamma interferon mRNA and protein on day 7, and (v) a smaller increase in the levels of interleukin-4 mRNA and protein on day 7. Hence, the immune responses to C. neoformans infection in the presence and absence of specific antibody were qualitatively similar, and antibody administration was associated with several subtle quantitative differences in immune response parameters that could translate into enhanced survival. MAb may function partly by down-regulating the inflammatory response and reducing host damage. Our findings demonstrate unexpected complexity in the interaction between specific MAb and other components of the host immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854246      PMCID: PMC127814          DOI: 10.1128/IAI.70.3.1571-1580.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors.

Authors:  M Stangel; A Compston
Journal:  J Neuroimmunol       Date:  2001-01-01       Impact factor: 3.478

Review 2.  Th1-Th2: reliable paradigm or dangerous dogma?

Authors:  J E Allen; R M Maizels
Journal:  Immunol Today       Date:  1997-08

3.  Involvement of endogenously synthesized interleukin (IL)-18 in the protective effects of IL-12 against pulmonary infection with Cryptococcus neoformans in mice.

Authors:  K Kawakami; M H Qureshi; T Zhang; Y Koguchi; S Yara; K Takeda; S Akira; M Kurimoto; A Saito
Journal:  FEMS Immunol Med Microbiol       Date:  2000-03

4.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

5.  Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of Legionella pneumophila pneumonia.

Authors:  K Tateda; T A Moore; J C Deng; M W Newstead; X Zeng; A Matsukawa; M S Swanson; K Yamaguchi; T J Standiford
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

6.  Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation.

Authors:  Z Q Wang; A S Bapat; R J Rayanade; A S Dagtas; M K Hoffmann
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

7.  Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferon-gamma-inducing cytokines.

Authors:  K Kawakami; M Hossain Qureshi; T Zhang; Y Koguchi; Q Xie; M Kurimoto; A Saito
Journal:  Cell Immunol       Date:  1999-10-10       Impact factor: 4.868

8.  A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.

Authors:  R Fleuridor; A Lees; L Pirofski
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

9.  Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection.

Authors:  M Feldmesser; Y Kress; P Novikoff; A Casadevall
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

10.  Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans.

Authors:  S S Mambula; E R Simons; R Hastey; M E Selsted; S M Levitz
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

View more
  28 in total

1.  Antibody immunity and natural resistance to cryptococcosis.

Authors:  N Trevijano-Contador; L Pirofski
Journal:  Curr Trop Med Rep       Date:  2019-04-04

Review 2.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

Review 3.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

5.  IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.

Authors:  Wendy A Szymczak; Rani S Sellers; Liise-anne Pirofski
Journal:  Am J Pathol       Date:  2012-02-16       Impact factor: 4.307

6.  Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.

Authors:  Luis R Martinez; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 7.  Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

8.  The Other Side of the Coin: Anti-inflammatory Antibody Therapy for Infectious Diseases.

Authors:  David L Goldman
Journal:  Infect Immun       Date:  2020-01-22       Impact factor: 3.441

9.  Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells.

Authors:  Johanna Rivera; Oscar Zaragoza; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

10.  The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus.

Authors:  R Buissa-Filho; R Puccia; A F Marques; F A Pinto; J E Muñoz; J D Nosanchuk; L R Travassos; C P Taborda
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.